{"id":30859,"date":"2023-06-01T13:58:48","date_gmt":"2023-06-01T13:58:48","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=30859"},"modified":"2024-07-25T12:12:12","modified_gmt":"2024-07-25T10:12:12","slug":"ipsen-sa-initiates-a-share-buy-back-program-to-cover-its-free-employee-share-allocation-plan","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-sa-initiates-a-share-buy-back-program-to-cover-its-free-employee-share-allocation-plan\/","title":{"rendered":"Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan"},"content":{"rendered":"\n
REGULATED INFORMATION<\/em><\/p>\n\n\n\n Ipsen initiates a share buy-back program<\/strong> Paris<\/strong> (France), <\/strong>1<\/strong> June<\/strong> 202<\/strong>3<\/strong> – Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 350,000, or about 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen\u2019s free employee share-allocation plan.<\/p>\n\n\n\n This program is made pursuant to the authorization granted by the Company\u2019s Combined Shareholders\u2019 meeting, held on 31 May 2023.<\/p>\n\n\n\n Ipsen<\/strong><\/p>\n\n\n\n Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of \u20ac3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company\u2019s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com<\/u><\/a>.<\/p>\n\n\n\n Contacts<\/strong><\/p>\n\n\n\n
to cover its<\/strong> free <\/strong>employee share-allocation plan<\/strong><\/p>\n\n\n\nInvestors<\/u><\/em><\/strong><\/td> <\/td><\/tr> Craig Marks<\/strong>
Vice President, Investor Relations
+44 7584 349 193
<\/td>Nicolas Bogler<\/strong>
Senior Manager, Investor Relations
+33 (0) 6 52 19 98 92
<\/td><\/tr>Media<\/u><\/em><\/strong><\/td> <\/td><\/tr> Amy Wolf<\/strong>
Vice President and Head of Corporate Brand Strategy
and Communications
+41 79 576 07 23
<\/td>Ioana Piscociu<\/strong>
Senior Manager,
Global Media Relations
+33 6 69 09 12 96
<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":9,"template":"","categories":[1766,1771],"tags":[],"class_list":["post-30859","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-news-pressrelease","category-regulated-info","entry"],"acf":[],"yoast_head":"\n